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Abstract 
Although omega-3 fatty acids have been a hot issue in nutrition for years, there remains a 
paucity of research on the topic of omega-3 fatty acid and pulmonary fibrosis and the mechanism 
is still unclear. The purpose of this research is to investigate the preventive effects of flaxseed oil 
for bleomycin-induced pulmonary fibrosis in rats and to find the possible underlying 
mechanisms. There are two experiments demonstrated in this dissertation, one is with various 
doses of flaxseed oil in the diet (0, 2.5, 5, 7.5, 10, 12.5, and 15 % (w/w)), and the other is with 
different times of sacrificing animals after oropharyngeal bleomycin treatment (days 7 and 21).  
 In the first study, three proteins including transforming growth factor-β (TGF-β), 
interleukin-1 (IL-1), and α-smooth muscle actin (α-SMA), commonly associated with fibrotic 
inflammation in the lung, were examined by Western blot and fatty acids composition of the 
diets and tissues were analyzed by gas chromatography (GC). Fifteen percent of flaxseed oil 
group significantly reduced septal and vascular thickness and fibrosis in the lung, and significant 
cardiac fibrosis in the heart. The amount of IL-1 and α-SMA decreased significantly as the 
amount of omega-3 fatty acids increased, whereas TGF-β did not change significantly.  
The next study further reported the time-course effect and potential underlying 
mechanisms. Both interleukin-6 (IL-6), a protein associated with fibrotic inflammation in the 
lung, and renin, an enzyme related to renin-angiotensin system, were examined by Western blot. 
The time-dependent increase of IL-6 in response to bleomycin treatment was reversed by 
flaxseed oil diet. Although renin was not significantly different in the kidney, it suggested that 
the renin-angiotensin system may be involved locally. In addition, the profiles of fatty acids in 
both liver and kidney tissues as measured by lipidomics demonstrated a significant increase of 
omega-3: omega-6 ratio in the flaxseed oil-fed groups. 
Overall, these results indicated for the first time that the omega-3 fatty acids rich in 
flaxseed oil inhibited the formation of pulmonary fibrosis in a dose-dependent manner - however 
the moderate dose of flaxseed oil was most effective - via anti-inflammatory mechanisms, which 
appears associated with the modulated fatty acid composition in the tissues. 
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Chapter 1 - Introduction 
Polyunsaturated fatty acids (PUFA) are represented essentially by two series, the omega-
6 and the omega-3 series, whose precursors are linoleic acid (18:2 omega-6, LA) and α-linolenic 
acid (18:3 omega-3, ALA).
1
 (Table 1-1)
1
 Their two derivatives arachidonic acid (20:4 omega-6, 
AA) and eicosapentaenoic acid (20:5 omega-3, EPA), respectively, have been shown to interfere 
with the synthesis of a variety of inflammatory factors and events. Moreover, omega-3 PUFAs 
also exert their known anti-inflammatory properties by direct action on the cellular production of 
major cytokine inflammation mediators, on endothelium dysfunction and on leucocyte 
chemotaxis.
3, 4
 Due to these effects, omega-3 PUFA have been used in the treatment of various 
chronic inflammatory conditions.
5
 
The typical Western diet is rich in omega-6 and relatively low in omega-3 PUFA.  
Among the fatty acids, the omega-3 PUFA is the one that seems to have the most powerful 
immunomodulatory actions, and among the omega-3 PUFA those from fish oil (EPA) and 
docosahexaenoic acid (DHA) are more biologically effective  than ALA, which is their precursor.  
Some of the properties of omega-3 PUFA take place through controlling of the quantities of 
diverse kinds of eicosanoids made, while other effects are connected with modifications in 
membrane fluidity, transcription factor activity, gene expression, and intracellular signaling 
pathways.  It is indicated from in vivo studies and clinical intervention studies that some omega-3 
fatty acids have powerful anti-inflammatory natures and might be helpful in the management of 
inflammatory and autoimmune disease.
6
   
Both LA and ALA are essential fatty acid and as such we have to get them from our diet. 
Since LA and ALA compete with one another for the enzymes responsible for the synthesis of 
various eicosanoids, an overload of one kind of fatty acids can interfere with the metabolism of 
the other, decreasing its incorporation into tissue lipids and modifying their biological effects.
7
 
An appropriate balance of essential fatty acids in the diet is important for maintaining good 
health and optimum performance in our body. Thus, the omega-6:omega-3 fatty acid ratio can 
impact our body’s metabolic and inflammatory state.8 In typical Western diet today, the ratio 
might be as much as 20-30:1.
9
 The optimal ratio recommended by Health Canada is 4:1 to 10:1,
 
the US Food and Drug Administration has not set the official recommendation yet.
7
 
2 
 
Although the benefits of fish oil which is rich in EPA are well known and popular in the 
market, flaxseed oil which is rich in ALA has not been investigated extensively. Flaxseed oil is a 
colorless to yellowish oil obtained from the seeds of the flax plant (Linum usitatissimum, also 
known as common flax or linseed). Flax is a blue flowering plant that produces small, flat seeds 
that range in color from golden yellow to reddish brown. Flaxseed is commonly found as whole 
seed, ground seed (powder or meal), or flaxseed oil.
10
 The oil in flaxseed is unique in that it is 
comprised of 73 % PUFA, 18 % MUFA, and 9 % saturated fatty acids, making it a low-saturated 
fat food.
11
 Flaxseed oil is known as the richest source of the omega-3 fatty acid, ALA, which 
involves approximately 55 % of the total fatty acids.
12
 The percent of fat as ALA in flaxseed is 
5.5 times higher than that in walnuts and canola oil, which are the second-richest products.
13
 
Flaxseed oil is generally safe when used appropriately, however large doses of 30 g/day or 
higher can cause loose stools and diarrhea. Some studies reported that ALA could increase the 
risk of prostate cancer, however it is found to be safe with ALA from plant sources, such as 
flaxseed oil.
14, 15, 16
 
Previously, our lab was the only lab to demonstrate that short chain omega-3 fatty acid 
(ALA) prevented bleomycin-induced pulmonary fibrosis. In addition, there have been no studies 
to determine the mechanism by which short chain omega-3 fatty acid prevent bleomycin-induced 
pulmonary fibrosis. Furthermore, the role of inflammation in the development of fibrosis has not 
been clearly defined. The purpose of this dissertation is to establish the preventive effect of 
omega-3 fatty acids in flaxseed oil on bleomycin-induced pulmonary fibrosis in rats and to find 
the possible underlying mechanisms.  
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Table 1-1 Omega-3 and omega-6 series of PUFA
2
 
Notation Common Name Formula 
C18:2Δ9,12 (n-6) Linoleic acid 
                              6*     12+                           9+ 
CH3- (CH2)4- CH= CH- CH2-CH= CH-(CH2)7-COOH 
C18:3Δ9,12,15 (n-3) α-Linolenic acid CH3- (CH2- CH= CH)3-(CH2)7-COOH 
C20:4Δ5,8,11,14 (n-6) Arachidonic acid CH3- (CH2)3-(CH2-CH=CH)4-(CH2)3-COOH 
C20:5Δ5,8,11,14,17 (n-3) Eicosapentaenoic acid CH3- (CH2- CH= CH)5-(CH2)3-COOH 
C22:6Δ4,7,10,13,16,19 (n-3) Docosahexaenoic acid CH3- (CH2- CH= CH)6-(CH2)2-COOH 
 
*Number of first carbon double bond from methyl end (n system) 
+Number of carbon double bond from carboxylic acid end (Δ system) 
4 
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Chapter 2 - Literature Review 
 Characteristics of Pulmonary Fibrosis 
 Definitions and Classification 
In 1868, Flint addressed a condition called “chronic pneumonitis” and observed that the 
fingertips of one patient presumed a bulbous form.
1, 2
  This was probably the first recorded case 
of the condition we now recognize as idiopathic pulmonary fibrosis (IPF), formerly known as 
cryptogenic fibrosing alveolitis.  It is an important and destructive disease with a median 
mortality of three years. It is worse than many cancers,
3
 and its incidence continues to rise, 
doubling in just over a decade (1990-2003).
4 
 
The interstitium is the microscopic space between the basement membranes of the 
alveolar epithelium and capillary endothelium and forms part of the blood-gas barrier. Idiopathic 
interstitial pneumonias (IIPs) are characterized by expansion of the interstitial compartment by 
inflammatory cells with associated fibrosis in many cases.
5
 The most recent international 
classification, published in 2002, divides IIPs into seven distinct groups – IPF, nonspecific 
interstitial pneumonia (NSIP), respiratory bronchiolitis interstitial lung disease (RBILD), 
desquamative interstitial pneumonia (DIP), acute interstitial pneumonia (AIP), cryptogenic 
organising pneumonia (COP) and lymphoid interstitial pneumonia (LIP).
6
  IPF is the most 
common form, explaining approximately 60 % of cases. IPF affects not only the interstitium but 
also the alveolar spaces, and is associated with a classic pathologic pattern called usual 
interstitial pneumonia (UIP).
6
  In UIP, “pneumonia” is applied to explain inflammation more 
willingly than infection, while “usual” indicates that the histological example is that most 
frequently detected.
7 
IPF has been characterized in the American Thoracic Society, European 
Respiratory Society, Japanese Respiratory Society, Latin America Thoracic Association 
(ATS/ERS/JRS/ALAT) consensus statement as “a specific form of chronic, progressive, 
fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, limited to 
the lungs, and associated with the histopathologic and/or radiologic pattern of usual interstitial 
pneumonia (UIP)”. 8. 9 
 
7 
 
 Epidemiology and Pathology 
IPF is slightly more general in males and typically presents in older adults with a mean 
age of onset of 67-69 years.
10
 In one of the best population-based studies from Bernalillo County 
in New Mexico, Coultas et al.
10
 recorded all new cases of interstitial lung disease registered over 
a 2-year period in a population of nearly half a million inhabitants.  They reported an 
incidence/prevalence (male/female) per 105 population of 11/7 and 20/13, respectively.  A 
Norwegian study reported an incidence/prevalence for hospitalized IPF of 4.3 and 20 per 
1,000,000.
11
 The incidence of IPF has been reported as growing by 11 % annually between 1991 
and 2003, signifying the number of recorded diagnoses of IPF is doubling every 8 years.
4
 
Typical symptoms of IPF contain chronic progressive exertional breathlessness, 
commonly along with a non-productive cough. As IPF progresses, breathlessness effects on 
activities of daily living, resulting in many patients becoming housebound, socially isolated and 
dejected.
12
 Clinical examination usually demonstrates end inspiratory fine crackles, which are 
often ‘high pitched’ or ‘Velcro-like’ in character. Up to 50 % of patients have finger clubbing, 
and those with more advanced disease may develop cor pulmonale.
13
 Histological biopsies in 
UIP reveal areas of normal lung with exchanging areas of interstitial inflammation and fibrotic 
zones formed predominantly of intense collagen with spread foci of proliferating fibroblasts 
(“fibroblastic foci”), a consistent finding of UIP.14 Untreated IPF follows a persistently 
progressive course in most patients.  Early studies usually overvalued survival rates, since 
patients with less destructive interstitial pathology such as NSIP were included in long-term 
follow-up.  More recent studies have demonstrated that median survival is approximately three 
years.
15
 Respiratory failure (39 %) is the most frequent reason of death, while heart failure 
(14 %), pulmonary cancer (10 %), ischaemic heart disease (10 %), infection (6 %) and 
pulmonary embolism (3 %) are other causes of mortality.
16
 
 
 Pathogenesis 
The cause of IPF is unknown.  The original ‘inflammation/alveolitis’ hypothesis 
proposed that IPF was a chronic inflammatory disease, taking place in response to an unknown 
stimulus, initiated progressive lung injury if left untreated, and ultimately fibrosis.
17
  The key 
hypothesis of the etiology of IPF includes irregular wound healing in response to numerous, 
8 
 
microscopic locations of continuing alveolar epithelial injury and activation cooperated with the 
development of patchy fibroblast-myofibroblast foci, which consequently progress to fibrosis.
18
 
The role of epithelial cell injury and fibrogenesis is critical to this hypothesis. Following 
epithelial cell injury from as yet unidentified triggers, there is accumulation of vascular exudates 
and inflammatory cells within the injured alveolar space. This epithelial cell injury results in the 
release of several proinflammatory and profibrotic mediators, including tumor necrosis factor 
alpha (TNFα), transforming growth factor-β (TGF-β), endothelin 1, metalloproteinases, and the 
coagulation mediator tissue factor, which may have synergistic effects on the induction of 
fibrosis.
19, 20
  
Various environmental stimuli have been suggested as risk factors for developing IPF, 
including cigarette smoking, antidepressants, chronic aspiration, metal and wood dusts, and 
infectious agents, including Epstein Barr virus.
7
  Familial IPF is rare, with a United Kingdom 
study reporting a incidence of 1.34 cases per million, explaining only 0.5-2.2 % of all IPF 
cases.
21
  A Finnish study reported similar findings, with familial IPF accounting for 3.3-3.7 % of 
cases.
22 
Patients with familial IPF are likely to occur at a younger age and some cases are related 
with surfactant protein C genes, with two mutations causing protein misfolding, triggering type 2 
epithelial cell injury.
23, 24
 Beyond lung transplantation, there are no confirmed effective therapies 
for the treatment of IPF so far.
25
 
 
 Use of Bleomycin in an Animal Pulmonary Fibrosis Model 
There are numerous different methods for modeling pulmonary fibrosis. They involve: 
contact with bleomycin, silica or fluorescein isothiocyanate (FITC); irradiation; or expression of 
certain genes through delivery of a viral vector or operation of a transgenic procedure. Among 
them, bleomycin remains the most frequently used agent and can be given directly into the 
airway by intratracheal or intranasal routes or systemically via subcutaneous, intraperitoneal or 
intravenous injection. With bleomycin there is ease of delivery, low cost, and quick development 
of fibrosis. It is widely used and accepted in literature, but it also has several weaknesses such as 
lack of many UIP features (temporal heterogeneity, fibroblastic foci, and prominent AEC 
hyperplasia) and inconsistent fibrosis development. However, in spite of its drawbacks, the 
animal model using bleomycin remains the best available experimental means. The model is 
9 
 
used for disease pathogenesis research and new pharmaceutical compound tests.
26
 Among these 
approaches, the method using a single dose of bleomycin delivered intratracheally is the most 
commonly used and referenced model. Bleomycin is a chemotherapeutic agent used in the 
treatment of a variety of tumors including lymphoma, squamous cell carcinoma and testicular 
carcinoma, due to its minimal immunosuppressive activity and low hematopoietic toxicity.  
However, this therapy is often complicated by a dose-dependent induction of interstitial 
pneumonitis that progresses into interstitial pulmonary fibrosis.
27
 Bleomycin is thought to cause 
lung damage through direct DNA strand breakage and generation of free radicals, thus inducing 
oxidative stress.
28
 When animals are treated with bleomycin, pulmonary fibrosis is induced and 
this response has been used as a model for studying mechanisms in the development of fibrotic 
lung diseases. Introduced via the respiratory system, bleomycin induces pathological 
disturbances similar to that of idiopathic pulmonary fibrosis commonly found in humans.
29
 
 
 Omega-3 Fatty Acids and Pulmonary Fibrosis 
 Lipids, Inflammation and the Immune System 
Inflammatory response is mainly a protective response that, when perpetuated, constitutes 
the mechanism for many diseases including pulmonary fibrosis. Activated immune system cells 
such as neutrophils, eosinophils, basophiles, monocytes and lymphocytes are capable of 
modifying the fatty acid profile of their membranes depending on the dietary lipid contribution. 
During inflammation, the processes of capture, rolling, adhesion, and subsequent transmigration 
of leukocytes through the endothelium are led by different chemotactic stimulation mechanisms 
and are determined by the fixation of complementary adhesion molecules between leukocyte and 
endothelial cell surfaces. In addition, there are several chemical mediators as chemotactic factors 
and cytokines that have an influence on these processes and modulate surface molecule gene 
expression as well as fixation intensity. The lipid profile of immune cell membranes will 
influence the production of chemical mediators, thus determining response intensity.
30 
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 Eicosanoids 
It has been found that bleomycin-induced pulmonary fibrosis produces a variety of 
eicosanoids associated with inflammation and collagen deposition.  Bleomycin has been shown 
to generate reactive oxygen species such as superoxide and hydroxyl radicals and to cause an 
increase in lipid peroxidation in microsomal fractions from the liver and the lung.  In addition, an 
increase in the availability of free radicals has been found to increase the synthesis of certain 
prostaglandins.  Both prostaglandins and leukotrienes have been implicated in the pathogenesis 
of a variety of inflammatory and immune processes.
29
 These eicosanoids stimulate lymphocyte 
and fibroblast proliferation commonly associated with collagen deposition in the lungs and cause 
pulmonary fibrosis, and it is known that the metabolic activity of eicosanoids are derived from 
different sources of fatty acids.
27
 They are products derived from the 20-carbon PUFAs, mainly 
AA and EPA. Their formation will depend on the composition of the leukocyte membrane 
phospholipids, in turn determined by the fatty acid profile of the diet.
31
 Eicosanoids have a very 
short life span, have a local autocrine or paracrine action and act on different biological 
processes like inflammation and hemostasis, helping to make the inflammatory process 
chronic.
32
 
Dietary fish oil has been found to protect against several inflammatory diseases, 
including rheumatoid arthritis, psoriasis, colitis, and asthma.  In addition, fish oil inhibits the 
inflammatory response to certain endotoxins.
33, 34, 35
 Dietary fish oil enriches phospholipids with 
omega-3 fatty acids, particularly EPA, while decreasing the content of AA.
36
 The commonly 
accepted mechanism for this reaction includes the change in eicosanoids from more biologically 
active prostaglandins/leukotrienes derived from AA to less biologically active ones derived from 
EPA or DHA. The different activity of eicosanoids derived from AA versus those derived from 
EPA is one of the most important mechanisms to explain the anti-inflammatory properties of 
omega-3 PUFA in many inflammatory diseases. (Figure 2-1
37
) Since eicosanoids are formed by 
enzymatic phospholipase cleavage of phospholipids found in cell membranes, dietary induced 
changes in the fatty acid composition of tissue could conceivably result in alterations of 
eicosanoid composition and thus, the level of activity in an inflammatory reaction.
36
 Eicosanoids 
associated with inflammation may therefore be attenuated by a change in dietary fatty acid. The 
omega-3 PUFAs in the diet can modify the composition of the micro-domains of T cell 
membranes, which participate actively in signal transduction mechanisms, modulating in vivo 
11 
 
production of pro-inflammatory cytokines coming from the omega-6 fatty acids. These fatty 
acids also diminish the accumulation of these cells in inflammation sites, either because of 
proliferation inhibition or increased apoptosis.
38, 39 
 
 
 
 
 
 
Linoleic acid (LA)     Linolenic acid (LNA) 
   (18:2 n-6)         (18:3 n-3) 
 
   Metabolism     DIET      Metabolism 
 
Arachidonic acid (AA)    Eicosapentaenoic acid (EPA) 
   (20:4 n-6)         (20:5 n-3) 
 
TXA2     PGE2     LTB4, LTC4, LTD4        TXA3     PGE3     LTB5, LTC5, LTD5 
Platelet    Inflammation mediators         Weaker   Weaker inflammatory activity 
aggregant            platelet 
      aggregant 
 
Figure 2-1 Interactions of n-3 PUFA with AA in the synthesis of eicosanoids with pro-
inflammatory activity
37
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 Cytokines 
Since inflammatory cytokine production is regulated by AA-derived eicosanoids and 
since dietary omega-3 PUFA affect production of these eicosanoids, it is expected that omega-3 
PUFA will affect cytokine production.
38
  
Transforming growth factor β (TGF-β) is an important modulator in the acute repair 
phase of a wound.  It is a profibrotic factor that affects many cellular functions, including 
fibroblast proliferation and chemotaxis, stimulating the synthesis and deposition of connective 
tissue, and the inhibition of connective tissue breakdown.  When levels of TGF-β are chronically 
elevated, excessive fibrosis results which is characterized by increased collage deposition.  In 
general, excess fibrosis contains increased concentrations of collagen, a rich blood supply and 
myofibroblasts, identified by α-smooth muscle actin (α-SMA) in cytoplasmic stress fibers. TGF-
β the major profibrotic growth factor during fibrogenesis is produced by fibroblasts, 
myofibroblasts, recruited smooth muscle cells, and macrophages.
40
 
It is known that production of Interleukin-1α (IL-1α), Interleukin-1 (IL-6) and TGF-β is 
altered in animal models of acute and chronic pulmonary diseases including those exposed to 
bleomycin.
41, 42
  Studies on IL-1α and IL-6 have established the primacy of these mediators in 
upregulation of adhesion molecules that are able to recruit leukocytes.
43
 Concerning lung 
inflammation, high concentrations of IL-6 have anti-inflammatory effects, apparently due to their 
ability to suppress IL-1α production, thereby inhibiting the upregulation of endothelial adhesion 
molecules.
44
 In vivo expression of IL-6 also significantly enhances lung TGF-β expression.45 
Since TGF-β is an important regulator of cell proliferation, differentiation, and formation of 
extracellular matrix and promoting tissue repair after a persistent inflammatory response
46
, IL-6 
also has an indirect pro-fibrotic effect.  
In recent years various in vivo studies have shown that certain PUFA contained in fish oil 
reduce inflammation, diminishing the response to inflammatory and profibrotic cytokines such as 
IL-1α and TGF-β.47 Fish oil has been employed for the treatment of several pathologies, such as 
glomerulonephritis, risk of cardiovascular diseases, rheumatoid arthritis, murine lupus nephritis, 
and even as an adjuvant in cancer therapy.  The biological effects of fish oil are attributed to 
omega-3 PUFA, mainly EPA and DHA.
47, 48 
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 Studies on Omega-3 Fatty Acids and Pulmonary Fibrosis 
 
There is a paucity of information concerning the potential benefits of omega-3 fatty acids 
in protecting against pulmonary fibrosis.  More studies and investigation seem to be needed in 
this area of study. 
Kennedy et al.
29
, reported that a diet rich in EPA could significantly improve bleomycin-
induced pulmonary fibrosis, possibly by means of modifications in eicosanoid metabolism. They 
examined the effect with 27 male Fischer 344 weanling rats, receiving one of two diets (standard 
lab diet or menhaden oil diet rich in EPA) for eight weeks.  In this experiment, they found that 
the increase in DNA content observed with bleomycin treatment was less in animals fed 
menhaden oil than in animals fed the laboratory diet.  In addition, menhaden oil diet significantly 
reduced the percentage of morphologically abnormal lung and lung hydroxyproline content 
following bleomycin treatment.  There was also a slight increase in the percent of neutrophils, 
eosinophils, and lymphocytes in bleomycin-treated animals receiving menhaden oil, although 
these increases did not reach statistical significance. 
In the study of Baybutt et al.
36
, they found that dietary fish oil, containing long chain 
omega-3 fatty acids, protected against monocrotaline (MCT, a pulmonary toxin) -induced 
pulmonary fibrosis.
38
 They did the experiment with 24 male Sprague-Dawley weanling rats, 
receiving either corn oil (15 %) or fish oil (13 % menhaden oil with the antioxidant tertiary butyl 
hydroquinone (30 mg/kg diet)) as the source of fat for 4 weeks. Septal fibrosis and occurrence of 
pneumonia were improved by dietary fish oil significantly. Vascular thickness was mildly 
reduced, and parenchymal inflammation and fibrosis were significantly reduced in the fish oil 
group treated with MCT, suggesting that inflammation of pulmonary parenchyma can be 
improved in the MCT model. 
Recently, Lee et al.
49
, demonstrated that diets with flaxseed prevented pulmonary fibrosis 
induced by thoracic X-ray radiation therapy (XRT), as they gave flaxseed supplementation to 
mice pre and post-XRT. Flaxseed is rich in high amount of omega-3 fatty acids and lignans with 
antioxidant properties. Mice were fed either a control diet or 10 % flaxseed diet, and 13.5 Gy 
thoracic XRT was treated after three weeks of diet.  Lungs were assessed at 24 hours, three 
weeks, and at four months respectively to see markers for lung damages. As a result, flaxseed-
fed mice had reduced expression of lung injury biomarkers such as Bax, p21 and TGF-β1 at 24 
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hours, and decreased oxidative lung damage at 3 weeks after XRT.  In addition, flaxseed-fed 
mice showed decreased lung fibrosis and reduced inflammatory cell influx into lungs at 4 months 
following XRT. Moreover, in vitro experiment from Karmiol et al.
50
 demonstrated that α-LNA 
directly inhibits bleomycin-induced IL-6 production by rat pulmonary endothelial cells. 
However, there is one study by Silva et al.
27
, suggested that fish oil does not prevent 
bleomycin-induced pulmonary fibrosis. The authors carried out the research with 24 adult female 
Swiss mice receiving either control diet or fish oil diet. However, there was a point of difference 
in this study. They administered the fish oil 15 days after the bleomycin treatment, which means 
they actually tested whether fish oil was effective in treating fibrosis rather that preventing it.  It 
is well known in the omega-3 fatty acid field that it takes about 2-4 weeks of feeding fish oil 
before the omega-3 fatty acids are incorporated into the phospholipids. 
Given published laboratory findings, Iwai et al.
51
 performed epidemiological studies in 
Japan to detect risk factors for IPF, on the basis of 1,311 Japanese IPF autopsy cases. And they 
also did IPF autopsy cases and live case control study was carried out of 86 subjects with IPF, 
and found an inverse association between fish intake and IPF development. With another case 
study in Japan, Miyake et al.
51
, found that there was a direct association between dietary omega-
6 PUFAs and IPF risk among 104 cases, who were over 40 years old. They revealed intake of 
saturated fatty acids, mono-unsaturated fatty acids, omega-6 PUFA and meat was independently 
associated with an increased risk of IPF.
51, 52
 
As shown above, omega-3 fatty acids are beneficial for inflammatory diseases, and they 
have the potential to prevent pulmonary fibrosis. However, as mentioned earlier, there is paucity 
of information concerning the potential benefits of omega-3 fatty acids in protecting against 
pulmonary fibrosis. In addition, many things regarding the underlying mechanisms are still not 
clear. More well conducted, randomized controlled trials appear warranted.  In addition, further 
studies to determine the optimal dose of omega-3 fatty acids for the prevention of pulmonary 
fibrosis in human are needed, as well as studies on how they are affected by time. 
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Chapter 3 - Enriched Short Chain Omega-3 Fatty Acids Protects 
Against Pulmonary Fibrosis in a Dose-dependent Manner 
  
 Abstract 
Dietary fish oil, containing long chain omega-3 fatty acids, has been previously found to 
protect against monocrotaline-induced pulmonary fibrosis. This study investigated the effects of 
flaxseed oil rich in short chain omega-3 fatty acids on bleomycin-induced pulmonary fibrosis. 
Forty-two Sprague-Dawley rats were assigned into seven groups with various doses of flaxseed 
oil at 0, 2.5, 5, 7.5, 10, 12.5, and 15 % (w/w) in the diet for one month prior to treating with 
bleomycin at 8 U/ kg oropharyngeally. Two weeks after bleomycin treatment, all of the rats were 
sacrificed and histological analyses of the lung and heart were performed. Three proteins 
including TGF-β, IL-1, and α-SMA, commonly associated with fibrotic inflammation in the lung, 
were examined by Western blot analysis. In addition, fatty acids composition of the diets and 
tissues were analyzed by GC. The fifteen percent flaxseed oil group significantly reduced septal 
and vascular thickness and fibrosis in the lung, and significant cardiac fibrosis in the heart. The 
amount of IL-1 and α-SMA decreased significantly as the amount of omega-3 fatty acids 
increased, whereas TGF-β did not change significantly. These results indicate that the omega-3 
fatty acid rich flaxseed oil inhibits development of pulmonary fibrosis in a dose-dependent 
manner which may be in part related to via anti-inflammatory mechanisms that appear to 
modulate fatty acid composition in the tissues. 
  
 Introduction 
Dietary fish oil which has long chain omega-3 fatty acids has been previously found to 
have protective effects against monocrotaline-induced pulmonary fibrosis.
1
 However, the 
effectiveness of short chain omega-3 fatty acid against fibrosis is not known. Therefore, this 
study investigated the effects of flaxseed oil, which has short chain omega-3 fatty acids, on 
bleomycin-induced pulmonary fibrosis. Bleomycin is a chemotherapeutic agent used in the 
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treatment of a variety of tumors.
2
 However, it has an adverse effect of inducing interstitial 
pulmonary fibrosis. The animal model using bleomycin remains the best available experimental 
methods for fibrosis. Bleomycin-induced pulmonary fibrosis is associated with the release of 
many kinds of eicosanoids also associated with inflammation and collagen deposition, and may 
be modulated by omega-3 fatty acids since the metabolic activities of eicosanoids derived from 
these fatty acids are typically less biologically active. 
Flax (Linum usitatissimum) is a blue flowering plant that produces small, flat seeds that 
range in color from golden yellow to reddish brown. Flaxseed is commonly found as whole seed, 
ground seed (powder or meal), or flaxseed oil.
3
 The oil in flaxseed is unique in that it is 
comprised of 73 % PUFA, 18 % MUFA, and 9 % saturated fatty acids, characterizing it as a low-
saturated fat food.
4
 Flaxseed oil is known as the richest source of the omega-3 fatty acid, ALA, 
which consists of approximately 55 % of the total fatty acids.
5
 The percent of fat as ALA in 
flaxseed is 5.5 times higher than that in walnuts and canola oil, which are the second-richest 
sources.
1
 
In the fibrotic lungs, pulmonary hypertension is often observed. In 1963, cor pulmonale 
was identified by the World Health Organization as “hypertrophy of the right ventricle (RV) 
resulting from diseases affecting the function and/or structure of the lungs, except when these 
pulmonary alterations are the result of diseases that primarily affect the left side of the heart, as 
in congenital heart disease.”6 The RV is a thin-walled and low-pressure chamber that pumps the 
same stroke volume as the left ventricle (LV) with around 25 % of the stroke work since the 
pulmonary vasculature has normally low resistance.
7
 The right coronary artery provides the 
blood supply to the RV free wall in both systole and diastole. When the pressure is overloaded 
constantly, the RV hypertrophies and enlarges, which results in both systolic and diastolic 
malfunction.
8
 Pulmonary fibrosis has an effect on right ventricular function by inflicting an 
afterload on the right ventricle and, therefore, eventually cardiac output is reduced as pulmonary 
fibrosis worsens. 
In this research three proteins commonly associated with fibrotic inflammation were 
examined: Interleukin-1 (IL-1), α-Smooth Muscle Actin (α-SMA), and Transforming Growth 
Factor-β (TGF-β). Decreases in any one of these proteins means an interruption of the 
inflammatory process. The fatty acid profiles were examined to determine whether flaxseed oil 
can modulate the fatty acid composition of the rats in pulmonary fibrosis.  In addition, 
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RV+septa/LV ratio of the heart was measured to determine whether pulmonary hypertension was 
produced by fibrotic lungs and if there was any preventive effects by flaxseed oil. A histological 
analysis of the heart was also performed to determine if flaxseed oil can modulate any of the 
above symptoms or pathologies. 
 
 Methods and Materials 
 Animals and Diets 
Forty-two male Sprague-Dawley weanling rats (Charles River Laboratories, Wilmington, 
MA) weighing about 40 - 50 g were housed individually in stainless steel cages at room 
temperature under a 12 h light : dark cycle (light 06:00 – 18:00 h) and a relative humidity of 
50 %. Animal care and use were approved by the Institutional Animal Care and Use Committee 
of Kansas State University. The animals were randomly assigned into seven different groups 
containing a control group with 0 % flaxseed oil. They were fed either an AIN 93G basal diet 
(Reeves et al. 1993, Table 3-1
9
) or a treatment diet that differs only in the type of dietary fat: 0 % 
flaxseed oil (15 % corn oil), 2.5 % flaxseed oil (12.5 % corn oil), 5 % flaxseed oil (10 % corn 
oil), 7.5 % flaxseed oil (7.5 % corn oil), 10 % flaxseed oil (5 % corn oil), 12.5 % flaxseed oil 
(2.5 % corn oil), and 15 % flaxseed oil (0 % corn oil) as the source of dietary fat. The rats were 
fed ad libitum and the purified diets were purchased from Dyets Inc. (Bethlehem, PA).  Food 
intake was recorded daily and body weights were measured weekly. The experimental design is 
shown in Figure 3-1. 
After four weeks on the diet, half of each diet group were anesthetized and administered 
8 U/kg body weight of bleomycin in 0.4 mL sterile saline by oropharyngeal delivery to minimize 
the stress of the animals.
10
 The other half of these groups were administered saline for the 
negative control groups.   
Two weeks after bleomycin treatment the rats were anesthetized with pentobarbitol.   
Liver, lungs, hearts, and kidneys were collected, weighed and used for chemical/histological 
studies. Surgical collection of organs was done in the lab separated from the animal facility to 
minimize stress to the animals. The histopathological analyses were carried by Dr. Molteni and 
resident pathologists in University of Missouri-Kansas City School of Medicine. 
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 Histopatholigical analysis 
Histological analysis of lung tissue was performed in a semi quantitative manner.
11, 12, 13
 
A degree scale of damage in the lung was carried out by blinded scoring of the degrees of 
severity by skilled pathologists. They scored by subjective comparisons with the normal tissue. 
The score ranged from 0 to 40, with the score 40 meaning extensive amounts of inflammation, 
fibrosis, or vasculitis (Appendix A). The right lung from each rat were inflated with 10 % 
buffered formalin and then placed in the same solution and fixed for one week. Sagittal sections 
embedded in paraffin, and sections 4 micro meters thick were stained by hematoxylin eosin for 
light microscopy. Masson’s trichrome staining for collagen, the marker for pulmonary fibrosis, 
was performed on representative samples from rats from each group. A lobe of liver from each 
animal also was collected at necropsy, immediately placed in 10 % buffered formalin, and fixed 
for 1 week. Hematoxylin eosin and Masson’s trichrome staining were performed on 4 micro 
meter-thick sections of this tissue. Hydroxyproline levels were determined (via a kit) as a 
measure of collagen synthesis. In addition, RV/LV ratio of the heart was evaluated. Blinded to 
the experimental group, hearts were dissected and weighed on an analytical balance, and 
RV+septa/LV ratio calculated.    
 
 Fatty Acids Analysis 
For fatty acids analysis, lipids were extracted from the lung and the liver and analyzed by 
Gas Chromatography using Folch method
14
 arranged by Kansas Lipidomics Research Center. To 
0.8 parts tissue (homogenized) in aqueous solution, 1 part chloroform and 2 parts methanol were 
added. After being shaken well, 1 part chloroform and 1 part water were added. After shaking 
again, it was centrifuged at low speed for 5 - 10 min. After removing the lower layer, 1 part 
chloroform was added. Then it was shaken, centrifuged, and the lower layer was again removed. 
After repeating this one more time, the combined lower layers were washed once with a small 
volume 1.0 M KCl and once with a small volume of water. After drying down, it was dissolved 
in 1 mL of chloroform. The extracted lipid was then derivatized. The fatty acid C15:0 internal 
standard was added to the lipid extract and fatty acids were methylated after hydrolysis by 
methanoic-HCl. 1 mL of 1.5 M methanoic HCl was added, bubbled with nitrogen gas for 10 s, 
then it was heated at 78 °C on heat block for 30 min. After cooling down, 2 mL of water and 2 
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mL of pentane were added and shaken for 15 s. Then it was centrifuges at low speed (700-800 
rpm) for 20 min. Upper pentane layers were collected to tubes containing sodium sulfate, then 2 
mL of pentane was added, shaken, and centrifuged again. The upper pentane layer was collected 
and combined with the previous layer extraction, and then all pentane layers were transfer to 
clean tubes. Pentane layers were dried down after transferred, and redissolved in small volume of 
hexane, then the sample would be ready to be injected in the Gas Chromatograph.  
Fatty acid composition of the lung tissue total lipids was determined by measuring the 
fatty acid methyl esters using a capillary gas chromatography with a flame ionization detector. 
The Gas chromatography-FID (Flame Ionization Detector) analysis was performed at the Kansas 
Lipidomics Research Center with a 6890N GC (Agilent Technologies) coupled to a FID. The GC 
was fitted with a HP-88 capillary column with a bis (Cyanopropyl) Polysiloxanes stationary 
phase (column length - 100 cm, internal diameter - 250 µm, ﬁlm thickness - 0.25 µm). Helium 
was used as the carrier gas at a flow rate of 1.2 mL/min. The back inlet was operating at a 
pressure and temperature of 32.36 psi and 275 °C respectively. Agilent 7683 autosampler was 
used to inject 1 µL of the sample in the split mode with a split ratio of 10:1. The GC temperature 
ramp was operated as follows, initial temperature of 70 °C, ramp 1 at 15 °C/min to 175 °C, ramp 
2 at 1 °C/min to a final temperature of 235 °C. The FID detector was operated at 260 °C. The 
hydrogen flow to the detector was 30 mL/min and air flow was 400 mL/min. The sampling rate 
of the FID was 20 Hz. The data were processed using Chemstation software. 
 
 Western Blot Analysis 
Protein analysis of IL-1, α-SMA, and TGF-β was conducted for stored lung tissues         
(-80 °C) via Western Blot analysis after protein extraction. Rat lung tissue was smashed into 
powder in liquid nitrogen, mixed with cell lysis buffer (5 mM Tris-HCl, pH 7.4, 2 mM EDTA, 
10 % Triton X-100, protease inhibitor cocktail and phosphatase inhibitor cocktail) and then 
homogenized. The lysate was then centrifuged in 20,000 rpm for 15 min at 4 °C. The supernatant 
was collected and sonicated for 10 s. After sonication, it was centrifuged with the speed of 
10,000 rpm for 15 min at 4 °C. The supernatant was collected and the protein concentration was 
measured by the Bio-Rad protein assay (Bio-Rad, Hercules, CA) with Bovine Serum Albumin 
(BSA) standards. Laemmli sample buffer (Bio-Rad, Hercules, CA) was used to mix with and 
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denature the proteins. The proteins were separated by 10 % SDS-PAGE gel and transferred to 
nitrocellulose membrane using Trans-Blot SD SEMI-DRY Transfer Cell (Bio-Rad, Hercules, CA) 
with 15 V for 20 min. The membrane was blocked with 5 % blocking buffer containing 5 % non-
fat milk at room temperature for 1 hr, and incubated with first antibody (IL-1, α-SMA, TGF-β, 
and β-actin (as the loading control)) (Santa Cruz Biotechnology Inc, Santa Cruz, CA) overnight. 
After the first antibody incubation, the membrane was washed with TDN-T (Tris-EDTA-NaCl 
with Tween 20) twice for 5 min each, then incubated with anti-mouse HRP-conjugation 
secondary antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA) for 1 hr. Finally the bands 
were visualized and protein density was determined using the Fluorchem densophotometry 
program. 
 
 Statistical Analysis 
All data were expressed as means ± SEM. Some of the histological data will be semi-
quantitative, that is a subjective evaluation by a trained pathologist.  The quantitative data was 
analyzed by one-way and two-way ANOVA using SAS software (SAS Institute, Cary, NC). 
Values of p less than 0.05 represented a significant difference. Post hoc t-tests (or Tukey) were 
performed with the differences between means when the overall main or interaction effect was 
significant at p < 0.05. 
 
 Results 
 Food Intake and Body Weight Gain 
The average amount of daily food intake was described in Figure 3-2 and 3. Overall, the 
food intake increased as the rats grew. There was not a significant difference between the saline 
groups and the bleomycin groups before the treatment with bleomycin. However, the daily food 
intake decreased after the treatment, and returned to pretreatment intake after one week. 
The body weight gain from the rats is shown in Figure 3-4 and 5. There was a similar 
tendency as shown in food intake. There was not a significance difference between saline groups 
and bleomycin groups, and the bodyweights increased as the rats grew. For bleomycin groups, 
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they showed a decreased body weights after the treatment with bleomycin, however they 
recovered after one week.  
 
 Organ Weights and Gross Evaluation 
There was no significant difference between control and treatment groups for the liver 
and the kidney. However, in the lung and the heart, the weights from the bleomycin treatment 
groups were significantly heavier than control groups (p < 0.01). Also, there were significant 
differences among flaxseed oil groups treated with bleomycin (p < 0.05) in the liver. The results 
are shown in Table 3-2. At gross evaluation, there were hemorrhaging and cobblestone 
appearances observed in the lungs of bleomycin treated rats. Among the flaxseed oil group, there 
was a less of tendency to observe discoloration or hemorrhaging, and cobblestone appearances 
compared to those without flaxseed oil from the groups with higher doses of flaxseed oil. 
 
 Histopathological Analysis of the Lung and the Heart 
Trichrome and H&E staining figures are shown in Figure 3-6 and 7. Saline, with low or 
high concentration of flaxseed oil, showed minimal inflammation. Staining for collagen with 
Trichrome also showed minimal presence of fibrosis. Severe inflammation occurred without 
flaxseed oil with septal and vascular thickness and marked collagen deposition. Fifteen percent 
flaxseed oil diet significantly reduced septal and vascular thickness and fibrosis when the 
damage was semi-quantified by blinded pathologists. Also, extensive lung damage was produced 
by bleomycin as seen in Figure 3-8. Comparing to saline control groups, all of the bleomycin 
treated groups showed lung damages. All were significant, therefore it could be predicted from 
these data that flaxseed oil was effective in preventing fibrosis, inflammation and vasculitis in 
the lung.  
For the histopathological analysis from the heart (Figure 3-9), significant cardiac fibrosis 
was seen, especially around vessels, in animals receiving bleomycin and 0 % flaxseed oil while it 
was not seen in the saline control group. Pretreatment of 15 % flaxseed oil protected the heart 
from the bleomycin effect. 
Figure 3-10 showed RV/LV ratios of the heart. Although there was a tendency of 
decreasing with the ratio as the dose of flaxseed oil in the diet increased, there was no significant 
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difference among groups. 15 % flaxseed oil group seemed exceeding saline control group, 
however, it was with a much larger standard deviation. 
 
 Fatty Acids Analysis from the Diet 
Fatty acids composition of the diet analyzed by GC is shown at Figure 3-11. Comparing 
with the control group (0 % flaxseed oil diet), it showed a significant increase of α-linolenic 
acids and a significant decrease of linoleic acids as the dose of flaxseed oil increased, proving 
that the flaxseed oil was rich in α-linolenic acids. (p < 0.01) 
 
 Fatty Acids Analysis from the Tissues 
The results from GC analysis with the tissues of the rats are shown in Figure 3-12. There 
was an increase of omega-3 fatty acid and a decrease of omega-6 fatty acid significantly among 
the rats as the dose of flaxseed oil increased in the diets (p < 0.001), demonstrating that the α-
linolenic acid within the dietary flaxseed oil is displacing the linoleic acid within the tissue. 
Especially, a significant increase of omega-3 fatty acid was observed from the group of 7.5 % 
when compared to the group of 5 % flaxseed oil diet (p < 0.05). Overall, the amount of omeg-6 
fatty acid was elevated with the bleomycin treatment. 
 
 Western Blot Analysis from the Lung 
 Interleukin-1 (IL-1) 
Figure 3-13 shows the result from the Western Blot analysis for IL-1 from the lung. The 
amount of IL-1 expression was significantly higher in the bleomycin groups than that of the 
saline groups (p < 0.0001). It gradually decreased as the dose of flaxseed oil increased in both of 
saline and bleomycin groups, showing that it did in a dose-dependent manner overall. However, 
IL-1 in 12.5 % saline group increased a little bit as compared with others. 
 Alpha-Smooth Muscle Actin (α-SMA) 
Alpha-SMA Western Blot analysis result from the lung is shown in Figure 3-14. The 
amount of α-SMA expression was higher in the bleomycin groups than that of the saline groups. 
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It significantly decreased with any dose of flaxseed oil, showing a dose-dependent manner. 
Especially with α-SMA, flaxseed oil showed the preventive effect with any doses from 2.5 %.  
 Transforming Growth Factor β (TGF-β) 
The result from Western Blot analysis of TGF-β is shown in Figure 3-15. Like other two 
proteins, the amount of TGF-β expression was also higher in the bleomycin groups than that of 
the saline groups. It significantly decreased at first comparing with the control group, however it 
showed an inconclusive result as the dose of flaxseed oil gets higher. 
 
 Discussion 
The main purpose of this study was to investigate the effectiveness of flaxseed oil, rich in 
short chain omega-3 fatty acids, on preventing bleomycin-induced pulmonary fibrosis in rat 
model, especially if there was a dietary dose-dependent effect of ALA in preventing bleomycin-
induced pulmonary fibrosis. Other studies regarding omega-3 fatty acids and preventing 
pulmonary fibrosis only demonstrated with a single dose of omega-3 fatty acids, either control 
diet or experimental diet
1, 15, 16
. This study was the first one to show if there was dose-dependent 
effect of ALA and to find appropriate dose of flaxseed oil to prevent pulmonary fibrosis. The 
overall results showed that preventive effect of flaxseed oil was dose-dependent at low doses, 
however it was most effective at the moderate dose. Especially fatty acid data suggested that 7.5 % 
seemed to be an optimal dose to enrich the tissues with omega-3 fatty acids. Pretreatment of 
flaxseed oil with diet for 4 weeks successfully prevented from pulmonary fibrosis and cardiac 
fibrosis as found in histological analyses of the lung and the heart. The severe inflammation and 
fibrosis observed in 0 % flaxseed oil diet induced by bleomycin treatment was significantly 
reduced with flaxseed oil diets.  
Another purpose of this study was to determine if flaxseed oil prevented pulmonary 
hypertension, which was often associated with pulmonary fibrosis. Although flaxseed oil diets 
successfully protected the heart from cardiac fibrosis, according to the results from RV/LV 
weights on the rats, they did not show significant improvement on the pulmonary hypertension 
induced by bleomycin-induced fibrosis. It was interesting since cardiac fibrosis seemed to be 
prevented in the heart by flaxseed oil, the pulmonary hypertension which was secondary to a 
fibrotic lung was not prevented by flaxseed oil in this study. 
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One of possible mechanisms underlying these preventive effects of flaxseed oil is through 
anti-inflammatory effects by omega-3 fatty acids. Omega-3 fatty acids are known to have anti-
inflammatory properties by direct action on the cellular production of major cytokine 
inflammation mediators, on endothelium dysfunction and on leukocyte chemotaxis. Due to these 
effects, omega-3 fatty acids have been used in the treatment of various chronic inflammatory 
conditions. It has been found that bleomycin-induced pulmonary fibrosis produces a variety of 
eicosanoids associated with inflammation and collagen deposition. Since eicosanoids are formed 
by enzymatic phospholipase cleavage of phospholipids found in cell membranes, dietary induced 
changes in the fatty acid composition of tissue could conceivably result in alterations of 
eicosanoid composition and thus, the level of activity in an inflammatory reaction. Therefore, 
eicosanoids associated with inflammation may be attenuated by a change in dietary fatty acid. 
One of the most important mechanisms to explain the anti-inflammatory properties of omega-3 
PUFA in many inflammatory diseases is the different activities of eicosanoids derived from AA 
versus those derived from EPA, since eicosanoids from EPA or DHA are less biologically active 
than those from AA
2
. From the results of fatty acids profile in diets and tissues analyzed by GC, 
it was demonstrated that the α-linolenic acid which was omega-3 fatty acid in flaxseed oil diet 
displaced linoleic acid in the tissues, which was omega-6 fatty acid. Especially, 7.5 % flaxseed 
oil diet group showed significant elevation of amount of omega-3 fatty acids in the tissues. 
Omega-3 fatty acids in flaxseed oil were effectively incorporated into the lung tissue, therefore 
they could exert the biologically protective effects. However, neither of EPA nor DHA was 
evaluated in this study, therefore further study should be performed with analysis with EPA and 
DHA considering of the low conversion rates from α-linolenic acid to EPA. 
In addition, since inflammatory cytokine production is regulated by AA-derived 
eicosanoids and since dietary omega-3 PUFA affects production of these eicosanoids, it was 
expected that omega-3 PUFA will affect cytokine production. In this study, biomarkers 
associated with fibrotic inflammation were used, IL-1, α-SMA, and TGF-β, through Western 
Blot analysis. The major advantages of the bleomycin-induced fibrosis models are the facts that 
it is easy to deliver the drug and takes a short time to demonstrate fibrosis.
17
 After bleomycin 
delivery, intense inflammation and edema with an elevation in cytokines such as tumor necrosis 
factor (TNF) α and IL-1β occur during the first week.18, 19 By approximately 14 days after the 
treatment, TGF-β peaks as well.20, 21 By the second and third week after the treatment of 
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bleomycin, patchy isolated collagen deposits resembling fibrosis builds up, with remarkable 
deposition of extracellular matrix components including fibronectin and collagen-1.
17
 Through 
the Western blot analysis, it was found that the inflammation in tissues decreased with flaxseed 
oil in dose-dependent manner, and moderate doses of flaxseed oil were more effective than the 
15 % of flaxseed oil. However TGF-β expression was inconclusive though it is the mostly well-
known profibrotic factor. It might be due to the short working period of TGF-β. Since the 
animals were sacrificed after two weeks of bleomycin treatment and TGF-β peaks at that time, 
the right time for TGF-β may have been missed. 
In addition, we used oropharyngeal delivery of bleomycin to rats instead of intratracheal 
delivery to minimize stress of the animals and improve the delivery of bleomycin. The rats were 
fed flaxseed oil incorporated into their food for one month prior to treating with bleomycin to 
determine whether these fatty acids will block or prevent the development of the pulmonary 
fibrosis. There was a concern about the delivery efficiency since it was the first time to apply this 
method in our lab, however the result of pulmonary fibrosis induced in organs showed that ample 
bleomycin was delivered. 
The purpose of this study was to determine if omega-3 fatty acids in flaxseed oil 
prevented bleomycin-induced pulmonary fibrosis, and how it differs along different doses of 
flaxseed oil. As shown in the results above, the omega-3 fatty acids in flaxseed oil diet 
successfully prevented pulmonary fibrosis and cardiac fibrosis in rats via modulation of fatty 
acids composition of the tissues and its associated anti-inflammatory effects. 
 
 
 
 
 
 
 
 
  
31 
 
 
Table 3-1 AIN-93G control diet
9
 
Ingredient  
                                                                                                                          g/kg diet 
Cornstarch  397.486 
Casein (≥85 % protein)  200.000 
Dextrinized cornstarch  
    (90-94 % tetrasaccharides)1 
 132.000 
Sucrose  100.000 
Soybean oil (no additives)    70.000 
Fiber2    50.000 
Mineral mix (AIN-93G-MX)    35.000 
Vitamin mix (AIN-93-VX)    10.000 
L-Cystine      3.000 
Choline bitartrate (41.1 % choline)3      2.500 
Tert-butylhydroquinone      0.014 
 
  1
Deytrose (Dyets, Bethlehem, PA) and Lo-Dex 10 (American Maize, Hammond, IN) meet these 
specifications. An equivalent product may also be used. 
   2
Solka-Floc, 200 FCC (FS&D, St. Louis, MO) or its equivalent is recommended. 
   3
Based on the molecular weight of the free base.  
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      Experimental period                                                                                                 (Weeks) 
                                                             Dietary treatment 
          0                                                                                    4                                             6 
 ▼ 
                                                                                                                                               ↑ 
     ▼ : Bleomycin administration 
      ↑  : Sacrificed point 
 
Figure 3-1 Experimental design 
The overall study period was for 6 weeks. After 4 weeks on the diet, half of each diet group were 
administered 8 U/kg body weight of bleomycin by oropharyngeal delivery. The other half of 
these groups were administered saline for the negative control groups. Two weeks after 
bleomycin treatment, the rats were sacrificed. 
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Figure 3-2 Food intake of the rats fed different doses of flaxseed oil in diet without 
treatment of bleomycin 
The average amount of daily food intake increased as the rats grew. There was no significant 
difference among saline groups, implying the taste of flaxseed oil did not affect the amount of 
food intake.  
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Figure 3-3 Food intake of the rats fed different doses of flaxseed oil in diet with treatment 
of bleomycin 
There was same tendency as with saline groups, the food intake increased as the animal grew.  
After the bleomycin treatment, the food intake decreased among bleomycin groups significantly, 
it might be due to the toxicity of bleomycin. However they returned to pretreatment intake after 
one week 
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Figure 3-4 Body weight change in rats fed diets containing different doses of flaxseed oil, 
without bleomycin treatment 
The body weights increased as the time passed and the rats grew. There was not a significant 
difference among the control and test groups. 
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Figure 3-5 Body weight change in rats fed diets containing different doses of flaxseed oil, 
with bleomycin treatment 
There was a similar tendency as shown in food intake. After the bleomycin treatment, body 
weights decreased as the food intake decreased and possibly from the toxicity of bleomycin. And 
they recovered after one week. 
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Table 3-2 Organ weights in rats fed diets containing different dose of flaxseed oil with or 
without bleomycin treatment 
Treatment Flaxseed oil Lung Liver Heart Whole Kidney 
Saline 
0.0 % 0.55 ± 0.071) 3.56 ± 0.31 0.37 ± 0.01 0.81 ± 0.01 
2.5 % 0.47 ± 0.04 3.36 ± 0.07 0.37 ± 0.01 0.77 ± 0.01 
5.0 % 0.40 ± 0.09 3.29 ± 0.07 0.38 ± 0.02 0.75 ± 0.09 
7.5 % 0.54 ± 0.16 3.23 ± 0.22 0.36 ± 0.01 0.75 ± 0.04 
10.0 % 0.71 ± 0.29 3.24 ± 0.10 0.35 ± 0.01 0.79 ± 0.03 
12.5 % 0.37 ± 0.09 3.43 ± 0.19 0.37 ± 0.01 0.78 ± 0.06 
15.0 % 0.51 ± 0.06 3.26 ± 0.22 0.33 ± 0.01 0.71 ± 0.08 
Bleomycin 
0.0 % 0.79 ± 0.39 3.76 ± 0.04a2) 0.39 ± 0.02 0.81 ± 0.03 
2.5 % 0.60 ± 0.11 3.65 ± 0.05ab 0.40 ± 0.02 0.83 ± 0.03 
5.0 % 1.18 ± 0.07 3.79 ± 0.16a 0.39 ± 0.01 0.86 ± 0.03 
7.5 % 0.80 ± 0.13 3.20 ± 0.05cd 0.39 ± 0.01 0.79 ± 0.03 
10.0 % 0.58 ± 0.04 2.92 ± 0.10d 0.40 ± 0.02 0.82 ± 0.04 
12.5 % 0.70 ± 0.12 3.35 ± 0.06bc 0.39 ± 0.01 0.74 ± 0.01 
15.0 % 1.18 ± 0.38 3.06 ± 0.06cd 0.37 ± 0.03 0.73 ± 0.04 
Significant factor(2-way)3) B A B - 
 
1) Data were expressed as mean ± SEM (n=3) in weight of organ/100g bodyweight.  
2) Values with different letter within the column in the same treatment group are 
significantly different at p < 0.05 by Tukey test.  
3) Statistical significance of experimental factors was calculated based on 2-way ANOVA. 
A : Effect of flaxseed oil diet with different doses was significant at p < 0.05. 
B : Effect of bleomycin treatment was significant at p < 0.05. 
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                 a)   Saline + 0 % flaxseed oil                           b)   Saline + 15 % flaxseed oil 
   
             c)   Bleomycin + 0 % flaxseed oil                    d)    Bleomycin + 15 % flaxseed oil 
Figure 3-6 Representative histological pictures with Mason’s Trichrome staining of lung 
from the rats fed diets containing different doses of flaxseed oil with or without bleomycin 
treatment 
Saline groups (figure a, b) showed minimal fibrosis with low or high doses of flaxseed oil. There 
are some collagen found in figure b, however it is due to the different part of the tissues. In 
figure c, severe inflammation and fibrosis were observed without flaxseed oil in bleomycin 
treatment, however in figure d, significantly reduced septal and vascular thickness and fibrosis 
were observed with 15 % flaxseed oil in diet with bleomycin treatment. 
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             a)    Saline + 0 % flaxseed oil                            b)    Saline + 15 % flaxseed oil 
   
            c)      Bleomycin + 0 % flaxseed oil                  d)     Bleomycin + 15 % flaxseed oil 
Figure 3-7 Histopathological pictures with H&E staining of lung from the rats fed diets 
containing different doses of flaxseed oil with or without bleomycin treatment 
There was the same tendency as shown with Trichrome staining of lung in figure 3-6. There was 
minimal inflammation among saline groups either low or high dose of flaxseed oil. In figure c 
without flaxseed oil in bleomycin treatment, severe inflammation was occurred, and significantly 
reduced septal and vascular thickness was observed with 15 % flaxseed oil in diet with 
bleomycin treatment in figure d. 
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Figure 3-8 Extensive lung damage produced by bleomycin versus saline groups 
* : Significant difference between the groups of saline and bleomycin treatment at p < 0.05 
*** : Significant difference between the groups of saline and bleomycin treatment at p < 0.001 
Compared with saline groups, all of the bleomycin treatment groups showed significant lung 
damages and they were improved by flaxseed oil in diet. Five percent flaxseed oil group was 
most effective in preventing of fibrosis, inflammation and vasculitis in the lung. 
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          a)     Saline + 0 % Flaxseed oil                                b)    Saline + 15 % Flaxseed oil 
  
         c)    Bleomycin + 0 % Flaxseed oid                       d)    Bleomycin + 15 % Flaxseed oil 
Figure 3-9  Histopathological pictures with Trichrome staining from the heart of the rats 
fed diets containing different doses of flaxseed oil with or without bleomycin treatment 
Significant cardiac fibrosis was observed in figure c, without flaxseed oil in bleomycin treatment, 
especially around vessels. In figure a and b saline control groups, there was no fibrosis seen in 
tissues. In figure d with 15 % flaxseed oil with bleomycin treatment, the tissue seemed as a 
control group, showing that flaxseed oil protected the heart from the bleomycin effect. 
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Figure 3-10 Right ventricle+saptal wall / Left ventricle weight ratio from the heart of the 
rats  
Although 15 % flaxseed oil group seemed to have preventive effect, it was with large standard 
deviation and without significance. There was no significant difference among groups, showing 
no improvement of pulmonary hypertension with flaxseed oil. 
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Figure 3-11 Major fatty acids profiles from the diets with different doses of flaxseed oil 
Fatty acids profiles in the diet analyzed by GC. As the dose of flaxseed oil increased in diet, the 
amount of α-linolenic acid increased and the amount of linoleic acid decreased significantly, 
showing that flaxseed oil was rich in α-linolenic acid. 
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Figure 3-12 Fatty acid composition of the liver from the rats fed different doses of flaxseed 
oil with our without bleomycin treatment 
Fatty acids profile from the liver of the rats performed by GC. The amount of α-linolenic acid 
increased as the dose of flaxseed oil increased, and the amount of linoleic acid decreased, 
demonstrating that α-linolenic acid in flaxseed oil replaced linoleic acid in the tissue. Among α-
linolenic acids, a significant increase of α-linolenic acid was observed from the group of 7.5 % 
flaxseed oil in diet when compared to the group of 5 % flaxseed oil diet. 
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Figure 3-13 Western Blot analysis of IL-1 from the lung of rats fed diets with different 
doses of flaxseed oil  
1) Values with different alphabet within the same color bars are significantly different at p < 
0.001. 
2) *Significant difference between saline control and bleomycin treatment group at p < 0.05. 
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Figure 3-14 Western Blot analysis of α-SMA from the lung of the rats fed diets with 
different doses of flaxseed oil 
1) Values with different letter within the same color bars are significantly different at p < 
0.001. 
2) * Significant difference between saline control and bleomycin treatment group at p < 0.05. 
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Figure 3-15 Western Blot analysis of TGF-β from the lung of rats fed diets with different 
doses of flaxseed oil 
1) Values with different letter within the same color bars are significantly different at p < 
0.001. 
2) * Significant difference between saline control and bleomycin treatment group at p < 0.05. 
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Chapter 4 - Short Chain Omega-3 Fatty Acids prevent Pulmonary 
Fibrosis in Time-course 
  
 Abstract 
We have previously found that dietary flaxseed oil, containing omega-3 fatty acids, 
protects against bleomycin-induced pulmonary fibrosis. This study evaluates the development of 
pulmonary fibrosis over time and potential underlying mechanisms. Forty Sprague-Dawley rats 
were assigned into four groups with either corn oil (15 % w/w) or flaxseed oil (15 % w/w) in the 
diet for one month prior to treating with bleomycin at 8 U / kg oropharyngeally. Half of the rats 
were sacrificed 7 days after bleomycin treatment. Both interleukin-6 (IL-6), a protein associated 
with fibrotic inflammation in the lung, and renin, an enzyme related to renin-angiotensin system, 
were examined by Western blot. The time-dependent increase of IL-6 in response to bleomycin 
treatment was significantly reversed by flaxseed oil diet. Although renin was not significantly 
different in the kidney, it suggested that the renin-angiotensin system may be involved locally. In 
addition, the profiles of fatty acids in both liver and kidney tissues as measured by lipidomics 
demonstrated a significant increase of omega-3 : omega-6 ratio in flaxseed oil-fed groups. These 
results indicated for the first time that flaxseed oil rich in omega-3 fatty acid might inhibit the 
formation of pulmonary fibrosis via suppressing inflammation. 
  
 Introduction 
As reported in Chapter 3, dietary flaxseed oil, which has short chain omega-3 fatty acids, 
was found to have protective effects against bleomycin-induced pulmonary fibrosis. Therefore, 
this study was conducted to further investigate the effects of flaxseed oil on bleomycin-induced 
pulmonary fibrosis and to determine the potential underlying mechanisms. Bleomycin is a 
chemotherapeutic agent used in the treatment of a variety of tumors.
1
 However, it has an adverse 
effect of inducing interstitial pulmonary fibrosis. Associated with bleomycin-induced pulmonary 
fibrosis is the release of many kinds of eicosanoids associated with inflammation and collagen 
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deposition, and they can be modulated by omega-3 fatty acids since the metabolic activities of 
eicosanoids are derived from different sources of fatty acids.  
Chapter 3 focused on the anti-inflammatory effects of flaxseed oil with different doses 
over time and detailed the effects on organs including the lung and heart. Therefore this chapter 
will further explore additional organs such as the liver and the kidney, and also possible 
underlying mechanisms other than inflammation. In addition, this study is a follow-up study of 
Dr. Baybutt
2
. Therefore the same animals have been used for both studies, they focused just on 
the lung. 
It is known that fibrosis can occur in the liver and kidney along with pulmonary disease. 
Thus we chose a different cytokine, IL-6 to see the potential anti-inflammatory effects of 
flaxseed oil on the liver and kidney against bleomycin-induced fibrosis. Another potential 
mechanism is by the renin-angiotensin pathway. Renin is an enzyme that participates in the 
body’s renin-angiotensin system (RAS), and angiotensin II (ANGII) is related to the 
inflammatory reaction involving NF-κB activation.3 Changes in renin expression would suggest 
a potential role for the renin-angiotensin pathway. 
 
 Methods and Materials 
 Animals and Diets 
Forty weanling male Sprague-Dawley rats weighing 40-60 g each were randomly 
assigned into one of four different groups and were fed an AIN 93G basal diet (Reeves et al. 
1993)
4
 containing either corn oil (15 % w/w) or flaxseed oil (15 % w/w) as the source of dietary 
fat. The animals were housed individually in stainless steel cages at room temperature under a 12 
h light : dark cycle (light 06:00 – 18:00 h) and a relative humidity of 50 %. Animal care and use 
were approved by the Institutional Animal Care and Use Committee of Kansas State University. 
The rats were fed ad libitum and the purified diets were purchased from Dyets Inc. (Bethlehem, 
PA). Food intake was recorded daily and body weights were measured weekly.   
After four weeks on the diet, half of each of these groups were anesthetized and 
administered 8 U/kg body weight of bleomycin in 0.4 mL sterile saline by oropharyngeal 
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delivery to minimize the stress of the animals.  The other half of these groups were administered 
saline for the negative control groups. 
Half of the rats were sacrificed 7 days after bleomycin treatment, and the others were 
sacrificed after 21 days. (Figure 4-1) The rats were anesthetized with pentobarbitol and organs 
including the heart, lung, liver, and kidney were collected for weighing and analysis. Lung, liver 
and kidneys were collected for chemical and histological studies.   
 
 Fatty Acids Analysis 
For fatty acids analysis, lipids were extracted from the liver and the kidney and analyzed 
by Gas Chromatography using Folch method
5
 arranged by Kansas Lipidomics Research Center. 
To 0.8 parts tissue (homogenized) in aqueous solution, 1 part chloroform and 2 parts methanol 
were added. After being shaken well, 1 part chloroform and 1 part water added. After shaking 
again, it was centrifuged at low speed for 5 - 10 min. After removing the lower layer, 1 part 
chloroform was added. Then it was shaken, centrifuged, and got removed the lower layer again. 
After repeating this one more time, the combined lower layers were washed once with a small 
volume 1.0 M KCl and once with a small volume of water. After drying down, it was dissolved 
in 1 mL of chloroform. Finishing with extraction, it was gone through derivatization. The fatty 
acid C15:0 internal standard was added to the lipid extract and fatty acids were methylated after 
hydrolysis by methanoic-HCl. 1 mL of 1.5 M methanoic HCl was added, bubbled with nitrogen 
gas for 10 s, then it was heated at 78 °C on heat block for 30 min. After cooling down, 2 mL of 
water and 2 mL of pentane were added and shaken for 15 s. Then it was centrifuges at low speed 
(700-800 rpm) for 20 min. Upper pentane layers were collected to tubes containing sodium 
sulfate, then 2 mL of pentane was added, shaken, and centrifuged again. The upper pentane layer 
was collected and combined with the previous layer extraction, and then all pentane layers were 
transfer to clean tubes avoiding taking any of sodium sulfate. Pentane layers were dried down 
after transferred, and redissolved in small volume of hexane, then the sample would be ready to 
be injected in the Gas Chromatograph.  
Fatty acid composition of the liver and the kidney tissue total lipids was determined by 
measuring the fatty acid methyl esters using a capillary gas chromatography with a flame 
ionization detector. The Gas chromatography-FID (Flame Ionization Detector) analysis was 
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performed at the Kansas Lipidomics Research Center with a 6890N GC (Agilent Technologies) 
coupled to a FID. The GC was fitted with a HP-88 capillary column with a bis (Cyanopropyl) 
Polysiloxanes stationary phase (column length - 100 cm, internal diameter - 250 µm, ﬁlm 
thickness - 0.25 µm). Helium was used as the carrier gas at a flow rate of 1.2 mL/min. The back 
inlet was operating at a pressure and temperature of 32.36 psi and 275 °C respectively. Agilent 
7683 autosampler was used to inject 1 µL of the sample in the split mode with a split ratio of 
10:1. The GC temperature ramp was operated as follows, initial temperature of 70 °C, ramp 1 at 
15 °C/min to 175 °C, ramp 2 at 1 °C/min to a final temperature of 235 °C. The FID detector was 
operated at 260 °C. The hydrogen flow to the detector was 30 mL/min and air flow was 400 
mL/min. The sampling rate of the FID was 20 Hz. The data were processed using Chemstation 
software. 
 
 Western Blot Analysis 
Protein analysis of IL-6, and renin was conducted for stored liver and kidney tissues via 
Western Blot analysis after protein extraction. Rat liver and kidney tissues were smashed into 
powder in liquid nitrogen, mixed with cell lysis buffer (5 mM Tris-HCl, pH 7.4, 2 mM EDTA, 
10 % Triton X-100, protease inhibitor cocktail and phosphatase inhibitor cocktail) and then 
homogenized. The lysate was then centrifuged in 20,000 rpm for 15 min at 4 °C. The supernatant 
was collected and sonicated for 10 s. After sonication, it was centrifuged with the speed of 
10,000 rpm for 15 min at 4 °C. The supernatant was collected and the protein concentration was 
measured by Bio-Rad protein assay (Bio-Rad, Hercules, CA) with Bovine Serum Albumin (BSA) 
standards. Laemmli sample buffer (Bio-Rad, Hercules, CA) was used to mix with and denature 
the proteins. The proteins were separated by 10 % SDS-PAGE gel and transferred to 
nitrocellulose membrane using Trans-Blot SD SEMI-DRY Transfer Cell (Bio-Rad, Hercules, CA) 
with 15 V for 20 min. The membrane was blocked with 5 % blocking buffer containing 5 % non-
fat milk at room temperature for 1 hr, and incubated with first antibody (IL-6, renin, and β-actin 
(as the loading control)) (R&D Systems, Minneapolis, MN, Santa Cruz Biotechnology Inc, Santa 
Cruz, CA) overnight. After the first antibody incubation, the membrane was washed with TDN-T 
(Tris-EDTA-NaCl with Tween 20) twice for 5 min each, then incubated with anti-mouse HRP-
conjugation secondary antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA) for 1 hr. 
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Finally the bands were visualized and protein density was determined using the Fluorchem 
densophotometry program. 
 
 Statistical Analysis 
All data were expressed as means ± SEM. One-way, two-way and three-way ANOVA 
using SAS software (SAS Institute, Cary, NC) were performed to test pre-determined 
hypotheses. Values of p less than 0.05 represented a significant difference. Post hoc t-tests (or 
Tukey) were performed with the differences between means when the overall main or interaction 
effect was significant at p < 0.05. 
 
 Results 
 Food Intake and Body Weight Gain 
The average amount of daily food intake among bleomycin groups was significantly less 
than the vehicle group after bleomycin treatment.(p < 0.01, Table 4-1) In 21 days groups, the 
decreased amount of daily food intake recovered as time went on, and after 2 weeks of 
bleomycin treatment, there was no significant difference between vehicle control and bleomycin 
treatment groups. 
The body weight gain or loss from the rats after bleomycin treatment is described in 
Table 4-2. At 7 days after the treatment, there was significantly less weight loss in the BF treated 
groups than the BC treated group. (p < 0.03) All the rats treated with bleomycin had weight loss 
for a while, but they began to gain weight again and after 21 days of treatment, most of the 
bleomycin treated rats recovered from the weight loss. 
 
  Organ Weights and Gross Evaluation 
Compared to the organs of the vehicle controls at 7 days group, the weights of all of the 
organs from bleomycin treated rats were all significantly less than control groups. (Table 4-3) 
Interestingly, the significant differences between diet groups were observed only in 7 days group. 
There was no significant difference in organ weights between diet groups in 21 days group. For 
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all of the organs, there was a significant difference between 7 days and 21 days groups, organ 
weights from 21 days groups were higher than those from 7 days since the animals were still 
growing. There were discoloration, hemorrhaging and a cobblestone appearance observed in the 
lungs of BC groups at 7 days, and more severely at 21 days. Comparing among bleomycin 
treated group, the lungs from BC group were appeared to have more discoloration and 
hemorrhaging than BF group. 
 
 Fatty Acids Analysis from the Diet 
Fatty acids composition of the diet analyzed by GC is shown at Table 4-4. The result was 
confirmed to be the same as in Chapter 3 since we used the same diets. Comparing with the 
control group (0 % flaxseed oil diet), it showed a significant increase of α-linolenic acids and a 
significant decrease of linoleic acids in 15 % flaxseed oil diet group, proving that the flaxseed oil 
was rich in α-linolenic acids. 
 
 Fatty Acids Analysis from the Tissues 
  The Liver 
The results from GC analysis with the liver tissues of the rats are shown in Figure 4-2. 
There was a huge significant increase in omega-3 : omega-6 ratio in all of the flaxseed oil-fed 
groups. As the amount of α-linolenic acid increased, the amount of linoleic acid decreased along 
with it. In the 7 days groups, there were significant differences in palmitic acid and stearic acid 
between corn oil group and flaxseed oil group. However, there was no significant difference with 
oleic acid in all groups. In the bleomycin treated groups, generally less amounts of fatty acids 
were observed in the 21 days group compared to the 7 days group in the rats fed corn oil diet, 
while there was an increase in flaxseed oil diet group compared with corn oil diet group. For 
EPA and DHA, a few amounts of them were found in the liver of rats, showing that the low 
conversion rate from α-linolenic acid. However, both of the amount of EPA and DHA 
significantly increased with flaxseed oil diet group. In addition, the amount of EPA and DHA in 
bleomycin treatment group was higher than those in vehicle group, implying higher conversion 
rate with bleomycin treatment. 
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  The Kidney 
Most of the fatty acids appeared to decrease in the flaxseed oil fed group except α-
linolenic acid, which significantly increased over all groups with flaxseed oil diet. Especially 
there were significant decrease in palmitic, stearic and oleic acid with 7 days bleomycin treated 
group. Comparing with vehicle and bleomycin treated groups, there was a tendency for stearic 
and linoleic acid to increase with bleomycin treatment, and it was attenuated in flaxseed oil diet 
groups. For EPA and DHA, it was interesting to note that the amount of EPA were not 
significantly different between corn oil and flaxseed oil diet in the kidney, implying there might 
be the basal amount of EPA in the kidney. There was no significant difference with EPA or DHA 
in bleomycin treatment groups. 
 
  Western Blot Analysis from the Tissues 
  Interleukin-6 (IL-6) from the Liver and Kidney 
Figure 4-3 and 4-4 showed the results from the Western Blot analysis of IL-6 from the 
liver and the kidney. The amount of IL-6 expression was significantly higher in the bleomycin 
groups than that of the vehicle groups (p < 0.05), and increase of IL-6 by bleomycin was 
significantly reversed by flaxseed oil diet in 7 days after treatment in the liver. Although there 
was no significant difference in the kidney, the amount of IL-6 was less expressed in 7 days 
flaxseed oil fed group (p < 0.05). 
 Renin from the Kidney 
The result from renin Western Blot analysis in the kidney is shown in Figure 4-5. It 
increased, but not significantly, in flaxseed oil groups among bleomycin treated groups. There 
also was no significant difference between 7 days and 21 days groups. 
  
 Discussion 
This study was performed to further investigate the effects of 15 % flaxseed oil on 
bleomycin-induced pulmonary fibrosis with time-course. As same as in Chapter 3, 15 % flaxseed 
oil diet successfully and significantly prevented from bleomycin-induced pulmonary fibrosis in 
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the lung of rats, which was revealed with histological data from our lab.
2
 The lungs of bleomycin 
treated flaxseed oil diet groups were obviously attenuated 21 days versus those of rats sacrificed 
after 7 days. 
In addition, the purpose of this study was to determine the potential underlying 
mechanisms with the liver and the kidney. Besides cardiac fibrosis, liver and kidney fibrosis 
were often observed in fibrotic lungs. As mentioned earlier in this chapter, this research was 
focused on the liver and the kidney. Especially for the kidney, renin-angiotensin system might be 
involved.  
Through Western blot analysis, significantly increased amount of IL-6 in control group 
with bleomycin treatment indicated that there was an ongoing process of inflammation induced 
by bleomycin in both of the liver and the kidney. Elevated expression of IL-6 due to bleomycin 
treatment was significantly reversed by flaxseed oil diet. IL-6 is an important cofactor for 
neutrophil activation and B cell stimulation, and it works at the early stage of inflammation
6
, as 
the results showed that the expression of IL-6 of 7 days group was much elevated than that of 
21days group. However in the kidney, the amount of IL-6 was very small when compared with 
that of the liver, implying there might not be severe inflammation in the kidney as produced in 
the liver. 
In both of liver and kidney tissues, there was a significant increase in amount of ALA, 
reducing the ratio of tissue omega-6 : omega-3 fatty acid. Less amount of ALA in bleomycin 
groups were observed, and flaxseed oil diet significantly changed the fatty acid composition in 
the liver and the kidney. In addition, the amount of LA significantly decreased in 21 days group. 
In this study, amount of EPA and DHA in the liver and the kidney was evaluated to determine 
the relationship with ALA to protect from pulmonary fibrosis and inflammation from bleomycin 
treatment, since dietary flaxseed oil does not contain both of EPA and DHA.  
It should be noted that the amount of EPA and DHA in the tissues was very small when 
compared to other study
7
 on prevention of pulmonary fibrosis, although they were significantly 
increased with flaxseed oil diet. The conversion rate of ALA to EPA is about 10 % in rats and 5 % 
in men
8, 9
. Women have higher conversion efficiency than men, might be due to the importance 
for demanding of fetus and neonate for DHA
10
. Due to these low conversion rates, dietary 
sources of ALA tend to be underestimated than those of EPA or DHA. However in this study, it 
clearly showed that ALA alone would be enough to play the important role for preventing 
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pulmonary fibrosis and inflammation. It is well known that ALA competes with LA for the 
metabolic enzyme and inhibit the conversion of LA to AA, giving rise to decreased amounts of 
substrate available for the formation of proinflammatory eicosanoids.
11
  
The angiotensin system is known to be triggered after tissue damage to support tissue 
repair, while tissue gets fibrosis when exacerbated. There is significant in vivo evidence 
suggesting that the angiotensin system is involved in pulmonary fibrosis.
12
 Earlier study revealed 
that constitutive expression of active TGF-β1 induced by human lung myofibroblasts was 
downregulated of collagen synthesis, therefore local upregulation of either angiotensin or TGF-
β1 expression could induce the other. Also, the synergy between two systems should be inhibited 
in order to block the development of lung fibrotic disease.
13
 Also recently, it was found that 
angiotensin signaling is related with fibrotic lungs.14 Although the kidney initiated renin-
angiotensin system, maybe involved, it is possible to and a number of studies support, the 
existence of “local” angiotensin (ANG) systems in diverse organs and tissues.15 It has to be noted 
that there is a key difference between the endocrine and local tissue ANG systems. It is that 
many local ANG systems have been shown to be not related with renin and angiotensin 
converting enzyme (ACE), but relatively related with other enzymes such as cathepsin D, tonin, 
cathepsin G, or chymase, for the enzymatic translation of angiotensinogen (AGT) to ANGII.
16
 
Therefore we need to think about those two possibilities together. Since in this study only renin 
was measured by Western blot analysis, we cannot convincingly state that renin-angiotensin 
system is related. Moreover, renin was not significantly different in the kidney. It might be 
because kidney fibrosis was not strong enough to determine the effect of renin, or it could 
suggest a potential mechanism with ‘local’ angiotensin systems regarding pulmonary fibrosis. 
Further study on angiotensin and receptors will be needed. 
In conclusion, these results indicated that the omega-3 fatty acids showed preventive 
effects from fibrosis in the liver and the kidney. Flaxseed oil diet significantly changed the fatty 
acid composition in the liver and the kidney, especially with low concentration of EPA and DHA. 
Although there was no significant difference of renin in the kidney, it suggests that the renin-
angiotensin system may be involved locally. With overall data from fatty acids analysis and 
Western blot analysis, ALA in flaxseed oil showed preventive effects for each of 7 days and 21 
days group, by attenuating the acute phase of inflammation in the liver and the kidney, and 
modulating fatty acid composition in the tissues sufficiently as time went on. 
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Figure 4-1 Experimental Design 
The overall study period was for 7 weeks. After 4 weeks on the diet, half of each diet group were 
administered 8 U/kg body weight of bleomycin by oropharyngeal delivery. The other half of 
these groups were administered saline for the negative control groups. Half of the animals were 
sacrificed 7 days after bleomycin treatment, and the rest of the animals were sacrificed 21 days 
after bleomycin treatment. 
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Table 4-1 Food intake averages by experimental group after bleomycin treatment
2
 
Group Weeks after bleomycin treatment 
Time Treatment 1 2 3 
7 days 
VC1) 22.32 ± 1.732) 
- - 
VF 22.15 ± 1.35 
BC 2.80 ± 1.13a3) 
BF 8.32 ±1.58b 
Significant factor 
(2-way) 
B - - 
21 days 
VC 21.62 ± 1.27 21.92 ± 1.42 20.63 ± 1.95 
VF 21.51 ± 1.43 18.85 ± 1.77 19.61 ± 1.91 
BC 11.17 ± 2.57 14.64 ± 2.84 16.96 ± 2.83 
BF 8.37 ± 1.30 17.29 ± 2.12 20.22 ± 2.03 
Significant factor 
(2-way)4) 
B B - 
 
1) VC : Vehicle Corn oil diet group, VF : Vehicle Flaxseed oil diet group,  
BC : Bleomycin Corn oil diet group, BF: Bleomycin Flaxseed oil diet group 
2) Data were expressed as mean (n=13-18). 
3) Values with different letter within the column in the same treatment group are 
significantly different at p < 0.01 by Tukey test. 
4) Statistical significance of experimental factors was calculated based on 2-way ANOVA. 
B : Effect of bleomycin treatment was significant at p < 0.05. 
 
Table 4-2 Body weight gain or loss shown by experimental group after bleomycin 
treatment
2
 
 VC1) VF BC BF 
7 days 23.6 ± 2.22) 31.0 ± 1.8 -71.7 ± 2.5 -37.6 ± 15.4*3) 
21 days 97.3 ±1.7 88.4 ± 11.9 4.2 ± 62.4 16.9 ± 31.0 
 
1) VC : Vehicle Corn oil diet group, VF : Vehicle Flaxseed oil diet group,  
BC : Bleomycin Corn oil diet group, BF: Bleomycin Flaxseed oil diet group 
2) Data are expressed as mean ± SEM (n=3-5). 
3) *Significantly different between BC and BF groups, p < 0.03. 
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Table 4-3 Weights of organs at 7 and 21 days after bleomycin treatment from the rats fed 
either corn oil or flaxseed oil diet
2
 
Days Group Lung3) Liver Heart Whole Kidney 
7 
VC1) 0.44 ± 0.012) 3.30 ± 0.06 0.55 ± 0.02a 0.82 ± 0.02 
VF 0.40 ± 0.01 3.27 ± 0.02 0.47 ± 0.02b 0.84 ± 0.02 
BC 1.55 ± 0.08a 3.78 ± 0.19a 0.49 ± 0.01a 1.06 ± 0.03a 
BF 1.00 ± 0.15b 3.23 ± 0.08b 0.43 ± 0.03b 0.94 ± 0.03b 
Significant Factor 
(2-way ANOVA)3) 
A, B, A*B A, A*B A B, A*B 
21 
VC 0.40 ± 0.01 3.02 ± 0.04 0.38 ± 0.01 0.75 ± 0.01 
VF 0.41 ± 0.01 2.94 ± 0.03 0.37 ± 0.02 0.79 ± 0.02 
BC 0.95 ± 0.29 3.14 ± 0.29 0.48 ± 0.06 0.90 ± 0.14 
BF 0.84 ± 0.18 3.20 ± 0.22 0.44 ± 0.05 0.88 ± 0.07 
Significant Factor 
(2-way ANOVA)4) 
B - B - 
Significant Factor 
(3-way ANOVA) 
A, B, C, A*B, 
B*C 
B, C A, B, C B, C 
 
1) VC : Vehicle Corn oil diet group, VF : Vehicle Flaxseed oil diet group,  
BC : Bleomycin Corn oil diet group, BF: Bleomycin Flaxseed oil diet group 
2) Data were expressed as mean ± SEM (n=3-5) in weight of organ/100g bodyweight. 
3) Lung and heart data were from Dr. Baybutt’s work.2 
4) Statistical significance of experimental factors was calculated based on 2-way and 3-way 
ANOVA. 
A : Effect of flaxseed oil diet was significant at p < 0.05. 
B : Effect of bleomycin treatment was significant at p < 0.05. 
C : Effect of time with bleomycin treatment was significant at p < 0.05. 
A*B : Interaction between flaxseed oil diet and bleomycin treatment was significant                     
           at p < 0.05. 
B*C : Interaction between bleomycin treatment and time with bleomycin treatment was   
          significant at p < 0.05. 
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Table 4-4 Fatty acids composition of the diet analyzed by GC
1)
 
Fatty acid Corn oil diet Flaxseed oil diet 
C16:0 2922.11 ± 124.672) 1248.55 ± 52.76 
C18:0 583.85 ± 25.16 1052.02 ± 41.99 
C18:1 n-9 cis 7551.47 ± 321.2 5027.15 ± 214.48 
C18:2 n-6 cis 14459.07 ± 621.28 3882.91 ± 165.84 
C18:3 n-3 252.895 ± 10.625 11992.8 ± 511.81 
 
1) Data were expressed as µg/g sample. 
2) Data were expressed as mean ± SEM. 
 
The diets were AIN-93G control diets containing either corn oil (15 % w/w) or flaxseed oil (15 % 
w/w) as the source of dietary fat.  
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c), d) 
 
 
Figure 4-2 Major fatty acids profile of the liver analyzed by GC.  
*Significantly different from vehicle group, p < 0.05 
**Significantly different from vehicle group, p < 0.01 
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c), d) 
 
 
Figure 4-3 Major fatty acids profiles in the kidney analyzed by GC 
*Significantly different from vehicle group, p < 0.05. 
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Figure 4-4 Western Blot analysis of IL-6 from the liver in the rats with or without 
bleomycin treatment 
1) CO : Corn Oil diet group, FO : Flaxseed Oil diet group 
*Significantly different from vehicle group, p < 0.05. 
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Figure 4-5 Western Blot analysis of IL-6 from the kidney in the rats with or without 
bleomycin treatment 
1) CO : Corn Oil diet group, FO : Flaxseed Oil diet group                                                                                        
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Figure 4-6 Western Blot analysis of renin from the kidney of rats with or without 
bleomycin treatment 
1) CO : Corn Oil diet group, FO : Flaxseed Oil diet group 
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Chapter 5 - Summary 
The overall purpose of this dissertation was to establish the preventive effect of omega-3 
fatty acids in flaxseed oil on bleomycin-induced pulmonary fibrosis in rats and to find the 
possible underlying mechanisms. Before this dissertation, very little was known about the 
flaxseed oil and prevention of bleomycin-induced pulmonary fibrosis. There have been no 
studies to determine the mechanism by which short chain omega-3 fatty acid prevent bleomycin-
induced pulmonary fibrosis, and further the role of inflammation in the development of fibrosis 
has not been clearly defined.  
 
Figure 5-1 summarized the major findings from this research and suggested possible 
mechanisms which might direct the future studies as following : 
- Measuring various kinds of cytokine to determine if ALA affects on each of phases 
with inflammation on pulmonary fibrosis over a period of time 
- Further analysis of local renin-angiotensin system and investigating the relationship 
with pulmonary fibrosis 
- Applying multiple deliveries of bleomycin instead a single treatment to induce 
pulmonary fibrosis more effectively 
- Exploring cardiac fibrosis and ALA : further preventive effects on the heart 
 
Although there were some limitations in this research, the results revealed for the first 
time that flaxseed oil diet successfully prevented bleomycin-induced pulmonary fibrosis in rats 
via modulation of fatty acids composition of the tissues and its associated anti-inflammatory 
effects, along with preventive effects on the heart, the liver, and the kidney. This dissertation is 
also looked at determining the optimal dose of flaxseed oil and underlying mechanism of 
mitigating bleomycin-induced pulmonary fibrosis in rats. Additional studies are warranted to 
investigate further unique mechanisms of ALA on idiopathic pulmonary fibrosis. 
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Figure 5-1 Summary of major findings from the dissertation 
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vasculitis in the 
lung 
Modulates fatty 
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By anti-
inflammatory 
effect through 
modulation of 
eicosanoids and 
cytokines 
α-SMA TGF-β 
IL-6 IL-1 
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angiotensin 
system 
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Appendix A - Pathology Score Sheet 
 
 
 
 
Appendix A-1 Pathology score sheet 
A degree of damage in the lung was carried out by scoring its degree of severity by blinded 
pathologists who were not aware of the treatment. They scored by subjective comparisons with 
the normal tissue. The score ranged from 0 to 40, with the score 40 meaning the most extensive 
degree of damage. 
